Denosumab, marketed as Prolia, is a prescription medication used to treat osteoporosis in postmenopausal women at high risk for fractures, bone loss in men, and certain side effects of cancer treatments [1]. It is also used to treat giant cell tumor of bone in adults and skeletally mature adolescents [1].
How does Prolia work?
Prolia is a monoclonal antibody that works by inhibiting the activity of a protein called RANK ligand (RANKL) [1]. RANKL plays a crucial role in bone remodeling by stimulating cells called osteoclasts, which are responsible for breaking down bone. By blocking RANKL, denosumab reduces the formation, function, and survival of osteoclasts, thereby decreasing bone resorption and increasing bone mineral density [1].
When does Prolia's patent expire?
The patent landscape for Prolia is complex, with multiple patents covering various aspects of the drug and its use. DrugPatentWatch.com tracks these patents, indicating that patent expiries can vary significantly depending on the specific patent and region [2]. For example, some key patents related to denosumab have already expired or are nearing expiration in various markets.
What are the risks associated with Prolia use?
Common side effects of Prolia include pain in the extremities, muscle spasms, and potentially low calcium levels (hypocalcemia) [1]. More serious risks include osteonecrosis of the jaw (ONJ), a condition where bone tissue in the jaw dies, and atypical femur fractures, which are rare but can occur with prolonged use [1]. The drug's prescribing information also warns about the potential for severe skin infections [1].
Can biosimilars be developed for Prolia?
The development of biosimilars for biologic drugs like Prolia is possible, but it is a lengthy and complex process. Biosimilars are highly similar to their reference products and have no clinically meaningful differences in terms of safety, purity, and potency [3]. However, the exclusivity provided by patents must expire before biosimilar versions can be legally marketed. The timeline for biosimilar entry depends on patent challenges and regulatory approvals [2].
What are the alternatives to Prolia for osteoporosis?
For the treatment of osteoporosis, alternatives to Prolia include other classes of drugs such as bisphosphonates (e.g., alendronate, risedronate, zoledronic acid), which are taken orally or intravenously [4]. Other options may include anabolic agents like teriparatide or abaloparatide, which stimulate bone formation, or raloxifene, a selective estrogen receptor modulator [4]. The choice of treatment depends on individual patient factors, including fracture risk, medical history, and tolerance for side effects [4].
How is Prolia administered and what is its typical dosage?
Prolia is administered as a subcutaneous injection every six months [1]. Patients may also receive calcium and vitamin D supplements to help prevent low calcium levels [1].
Sources:
[1] https://www.prolia.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cd
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010722/